Skip to main content

Table 3 Baseline parameters and the reduction of body weight or HbA1c in the unchanged treatment group

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Baseline parameters

Reduction of body weight

Reduction of HbA1c

 

Univariate

Multivariate p value

Univariate

Multivariate p value

 

r

p value

 

r

p value

 

Age

−0.178

0.307

 

−0.147

0.401

 

Male

−0.240

0.165

 

−0.053

0.764

 

BMI

0.502

0.003

0.051

0.406

0.017

0.448

WC

0.294

0.208

 

0.243

0.302

 

Duration of DM

−0.162

0.208

 

−0.052

0.784

 

SBP

−0.370

0.029

0.243

0.011

0.949

 

DBP

−0.111

0.527

 

0.238

0.169

 

FPG

−0.107

0.540

 

−0.126

0.470

 

HbA1c

0.165

0.344

 

0.863

<0.001

0.266

LDL-C

0.063

0.732

 

0.399

0.024

0.490

TG

−0.145

0.427

 

0.370

0.037

0.420

HDL-C

−0.035

0.850

 

−0.360

0.043

0.537

AST

0.331

0.069

 

0.218

0.240

 

ALT

0.477

0.004

0.543

0.393

0.022

0.418

sCPR

0.050

0.822

 

0.256

0.239

 

Insulin dose

0.105

0.555

 

0.023

0.897

 

Insulin dose U/kg

0.015

0.933

 

−0.064

0.718

 

Eating behavior

0.808

0.003

0.824

0.525

0.098

0.400

Previous treatment

Insulin

0.214

0.217

 

−0.344

0.043

0.545

BG

0.017

0.921

 

−0.165

0.343

 

SU

−0.190

0.273

 

−0.297

0.083

0.648

αGI

−0.054

0.757

 

−0.026

0.881

 

TZD

−0.049

0.784

 

0.083

0.635

 

DPP4i

0.031

0.861

 

−0.127

0.466

 

Glinide

−0.036

0.836

 

−0.002

0.992

 
  1. Reduction of body weight or HbA1c from baseline to 1 year was analyzed with baseline clinical parameters in 35 subjects whose anti-diabetic agents were not altered except dosage of liraglutide.
  2. BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose, HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase, ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us